[HTML][HTML] Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with …
ME Dudley, CA Gross, RPT Somerville… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2013•ncbi.nlm.nih.gov
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating
Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma - PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content
Main Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User
Guide Journal List J Clin Oncol PMC3731980 Other Formats PubReader PDF (185K) Actions
Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles …
Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma - PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content
Main Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User
Guide Journal List J Clin Oncol PMC3731980 Other Formats PubReader PDF (185K) Actions
Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles …
Abstract
Purpose
Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma can cause durable tumor regressions. The optimal TIL product for ACT is unknown.
ncbi.nlm.nih.gov